A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
- 1 July 2007
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 17 (4) , 771-776
- https://doi.org/10.1111/j.1525-1438.2007.00886.x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301Journal of Clinical Oncology, 2006
- Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinomaCancer, 2006
- Managing Patients Treated with Bevacizumab Combination TherapyOncology, 2005
- Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast CancerOncology, 2005
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerGynecologic Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- The Biology of Vascular Endothelial Growth FactorEndocrine Reviews, 1997